Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by G1 Therapeutics

Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
G1 Therapeutics Announces Closing of Offering of Common Stock
From G1 Therapeutics
Via GlobeNewswire
Tickers GTHX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.